Evolving Strategies for the Management of Core-Binding Factor Acute Myeloid Leukemia

被引：0
作者：
O'Brien, Susan
Borthakur, Gautam [1 ,2 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA
[2] Univ Texas MD Anderson Canc Ctr, Dev Therapeut, Div Canc Med, Houston, TX 77030 USA
来源：
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY | 2020年 / 18卷 / 11期
关键词：
ACUTE MYELOGENOUS LEUKEMIA; GEMTUZUMAB OZOGAMICIN; RISK STRATIFICATION; CHEMOTHERAPY; CYTARABINE; FLUDARABINE; SURVIVAL; OUTCOMES; AML;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：4
相关论文
共 18 条
  • [1] Response kinetics and factors predicting survival in core-binding factor leukemia
    Boddu, Prajwal
    Gurguis, Christopher
    Sanford, David
    Cortes, Jorge
    Akosile, Mary
    Ravandi, Farhad
    Garcia-Manero, Guillermo
    Patel, Keyur P.
    Kadia, Tapan
    Brandt, Mark
    Maduike, Rita
    Kantarjian, Hagop
    Borthakur, Gautam
    [J]. LEUKEMIA, 2018, 32 (12) : 2698 - 2701
  • [2] Treatment of Core-Binding-Factor in Acute Myelogenous Leukemia With Fludarabine, Cytarabine, and Granulocyte Colony-stimulating Factor Results in Improved Event-free Survival
    Borthakur, Gautam
    Kantarjian, Hagop
    Wang, Xuemei
    Plunkett, William K., Jr.
    Gandhi, Varsha V.
    Faderl, Stefan
    Garcia-Manero, Guillermo
    Ravandi, Farhad
    Pierce, Sherry
    Estey, Elihu H.
    [J]. CANCER, 2008, 113 (11) : 3181 - 3185
  • [3] Gemtuzumab ozogamicin with fludarabine, cytarabine, and granulocyte colony stimulating factor (FLAG-GO) as frontline regimen in patients with core binding factor acute myelogenous leukemia
    Borthakur, Gautam
    Cortes, Jorge E.
    Estey, Elihu E.
    Jabbour, Elias
    Faderl, Stefan
    O'Brien, Susan
    Garcia-Manero, Guillermo
    Kadia, Tapan Mahendra
    Wang, Xuemei
    Patel, Keyur
    Luthra, Rajyalakshmi
    Koller, Charles
    Brandt, Mark
    Ravandi, Farhad
    Kantarjian, Hagop
    [J]. AMERICAN JOURNAL OF HEMATOLOGY, 2014, 89 (10) : 964 - 968
  • [4] Survival Is Poorer in Patients With Secondary Core-binding Factor Acute Myelogenous Leukemia Compared With De Novo Core-binding Factor Leukemia
    Borthakur, Gautam
    Lin, E.
    Jain, Nitin
    Estey, Elihu E.
    Cortes, Jorge E.
    O'Brien, Susan
    Faderl, Stefan
    Ravandi, Farhad
    Pierce, Sherry
    Kantarjian, Hagop
    [J]. CANCER, 2009, 115 (14) : 3217 - 3221
  • [5] Optimization of Chemotherapy for Younger Patients With Acute Myeloid Leukemia: Results of the Medical Research Council AML15 Trial
    Burnett, Alan K.
    Russell, Nigel H.
    Hills, Robert K.
    Hunter, Ann E.
    Kjeldsen, Lars
    Yin, John
    Gibson, Brenda E. S.
    Wheatley, Keith
    Milligan, Donald
    Kjeldsen, Lars
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (27) : 3360 - +
  • [6] Identification of Patients With Acute Myeloblastic Leukemia Who Benefit From the Addition of Gemtuzumab Ozogamicin: Results of the MRC AML15 Trial
    Burnett, Alan K.
    Hills, Robert K.
    Milligan, Donald
    Kjeldsen, Lars
    Kell, Jonathan
    Russell, Nigel H.
    Yin, John A. L.
    Hunter, Ann
    Goldstone, Anthony H.
    Wheatley, Keith
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (04) : 369 - 377
  • [7] Repetitive cycles of high-dose cytarabine benefit patients with acute myeloid leukemia and inv(16)(p13q22) or t(16;16)(p13;q22):: Results from CALGB 8461
    Byrd, JC
    Ruppert, AS
    Mrózek, K
    Carroll, AJ
    Edwards, CG
    Arthur, DC
    Pettenatti, MJ
    Stamberg, J
    Koduru, PRK
    Moore, JO
    Mayer, RJ
    Davey, FR
    Larson, RA
    Bloomfield, CD
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (06) : 1087 - 1094
  • [8] Therapy-Related Acute Myeloid Leukemia With t(8;21) (q22;q22) Shares Many Features With De Novo Acute Myeloid Leukemia With t(8;21)(q22;q22) but Does Not Have a Favorable Outcome
    Gustafson, Steven A.
    Lin, Pei
    Chen, Su S.
    Chen, Lei
    Abruzzo, Lynne V.
    Luthra, Rajyalakshmi
    Medeiros, L. Jeffrey
    Wang, Sa A.
    [J]. AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2009, 131 (05) : 647 - 655
  • [9] Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials
    Hills, Robert K.
    Castaigne, Sylvie
    Appelbaum, Frederick R.
    Delaunay, Jacques
    Petersdorf, Stephen
    Othus, Megan
    Estey, Elihu H.
    Dombret, Herve
    Chevret, Sylvie
    Ifrah, Norbert
    Cahn, Jean-Yves
    Recher, Christian
    Chilton, Lucy
    Moorman, Anthony V.
    Burnett, Alan K.
    [J]. LANCET ONCOLOGY, 2014, 15 (09) : 986 - 996
  • [10] Outcomes of Patients With Relapsed Core Binding Factor-Positive Acute Myeloid Leukemia
    Khan, Maliha
    Cortes, Jorge
    Qiao, Wei
    Alzubaidi, Mohanad A.
    Pierce, Sherry A.
    Ravandi, Farhad
    Kantarjian, Hagop M.
    Borthakur, Gautam
    [J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2018, 18 (01) : E19 - E25
12